ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluate the Safety & Assess Local and Systemic PK of DS003 Vaginal Tablets Administered to Healthy HIV-negative Women

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02877979
Recruitment Status : Completed
First Posted : August 25, 2016
Last Update Posted : August 24, 2017
Sponsor:
Information provided by (Responsible Party):
International Partnership for Microbicides, Inc.

Brief Summary:
A double-blind, randomised, placebo-controlled, dose escalation trial to evaluate the safety and to assess local and systemic pharmacokinetics of ds003 vaginal tablets administered to healthy HIV-negative women.

Condition or disease Intervention/treatment Phase
HIV Drug: DS003 vaginal tablet Drug: Placebo Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Double-blind, Randomised, Placebo-controlled, Dose Escalation Trial to Evaluate the Safety and to Assess Local and Systemic Pharmacokinetics of DS003 Vaginal Tablets Administered to Healthy HIV-negative Women
Actual Study Start Date : November 18, 2015
Actual Primary Completion Date : August 26, 2016
Actual Study Completion Date : August 26, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: DS003 vaginal tablet
participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17.
Drug: DS003 vaginal tablet
The trial will be conducted in three cohorts of 12 women each. In each cohort, participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17. In each cohort, therefore, 9 participants will receive DS003 vaginal tablets and 3 participants will receive placebo vaginal tablets.

Placebo Comparator: placebo
participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17.
Drug: Placebo



Primary Outcome Measures :
  1. To evaluate the safety of three escalating doses of DS003 (1 mg, 3 mg and 10 mg), administered in a vaginal tablet formulation, to healthy, HIV-negative female volunteers. [ Time Frame: 12 weeks ]
    Gynaecological assessments, including pelvic examination and colposcopy


Secondary Outcome Measures :
  1. To assess the local (vaginal fluids) and systemic (plasma) DS003 PK profile and the 24 hour cervical tissue concentration when administered in three escalating doses of a vaginal tablet formulation. [ Time Frame: 12 weeks ]
    Measurement of DS003 concentrations in plasma, vaginal fluids and cervical tissue collected at various time points after administration of the vaginal tablet(s).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Women must meet all of the following criteria to be eligible for enrolment:

  1. Women ≥ 18 and ≤ 45 years of age who can give written informed consent
  2. BMI of ≥ 18 and < 30 kg/m2
  3. Vital signs within normal limits and no clinically significant ECG findings
  4. Available for all visits and consent to follow all procedures scheduled for the trial
  5. Healthy, based on medical history, vital signs, physical examination, urinalysis (dipstick and microscopy), laboratory evaluations for genital infections (bacterial vaginosis, gonorrhoea, chlamydia and trichomonas) and laboratory evaluations for haematology and biochemistry
  6. HIV-negative as determined by an HIV test at the time of screening
  7. On a stable form of contraception, defined as:

    • A stable oral contraceptive regimen for at least 2 months prior to enrolment, OR
    • Transdermal contraceptive patch for at least 3 months prior to enrolment, OR
    • Subcutaneous implant inserted at least 3 months prior to enrolment, OR
    • Long-acting progestins for at least 2 consecutive injections, OR An IUD inserted (with no vaginal or gynaecological complaints associated with its use) at least 3 months prior to enrolment, OR
    • Have undergone surgical sterilisation at least 3 months prior to enrolment AND be willing to use oral contraceptives if necessary to delay menstruation while taking part in the trial
  8. Upon pelvic examination and colposcopy at screening and visual inspection of the cervix at the time of enrolment, the cervix and vagina appear normal as determined by the Investigator
  9. Asymptomatic for urogenital infections at the time of screening (if a woman is diagnosed with any curable STI, either clinically or by laboratory test at the time of screening, she must complete the full course of treatment and have a healthy genital tract before being considered for potential re-screening)
  10. Willing to refrain from the use of topical vaginal medications, vaginal products or objects, including tampons, female condoms, cotton wool, rags, diaphragms, cervical caps (or any other vaginal barrier method), douches, lubricants, vibrators/dildos, and drying agents for 7 days prior to enrolment and for the duration of the trial
  11. Documentation of no abnormality on cervical cytology, including grossly bloody smear, within 90 days prior to screening
  12. Willing to refrain from participation in any other research trial for the duration of this trial
  13. Willing to provide adequate locator information for trial retention purposes and be reachable per local standard procedures, e.g. by home visit or telephone, or via family or close neighbour contacts (confidentiality to be maintained)
  14. Willing to agree to abstain from all the following for a total of 2 days (48 hours) prior to each trial visit, and for a total of 3 days (72 hours) after the biopsy procedure:

    Penile-vaginal intercourse

    • Oral contact with her genitalia

  15. Hepatitis B and C negative at the time of screening

Exclusion Criteria:

Women who meet any of the exclusion criteria below are not eligible:

  1. Currently pregnant or had their last pregnancy outcome within 3 months prior to screening
  2. Currently breast-feeding
  3. Currently or within 2 months of participation in any other clinical research trial involving investigational or marketed products prior to screening
  4. Untreated symptomatic urogenital infections, e.g. urinary tract or other sexually transmitted infections, or other gynaecological conditions such as vaginal itching, pain, or discharge, prior to enrolment
  5. Have a Grade 2 or higher pelvic examination finding, according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events; Addendum 1 Female Genital Grading Table for Use in Microbicide Studies
  6. History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding, urethral obstruction, incontinence or urge incontinence
  7. Current vulvar or vaginal symptoms/abnormalities that could influence the trial results
  8. Cervical cytology at screening that requires cryotherapy, biopsy, treatment, or further evaluation
  9. Symptomatic genital herpes simplex virus (HSV) infection or a history of genital herpetic infection
  10. Any Grade 2, 3 or 4 haematology, biochemistry or urinalysis laboratory abnormality at baseline (screening) according to the current version of the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events
  11. Unexplained, abnormal bleeding per vagina during or following vaginal intercourse, or gynaecologic surgery within 90 days prior to enrolment
  12. Any history of anaphylaxis or severe allergy resulting in angioedema; or a history of sensitivity/allergy to latex
  13. Any serious acute, chronic or progressive disease (e.g. any known history of neoplasm, cancer, diabetes, epilepsy, cardiac disease, autoimmune disease, HIV, AIDS, or blood dyscrasias), or signs of cardiac disease, renal failure, or severe malnutrition
  14. Have undergone a hysterectomy
  15. History of drug or substance abuse within 1 year of enrolment
  16. Use of tobacco within 6 months of enrolment
  17. Not willing to abstain from alcohol from 14 days prior to enrolment until completion of trial participation
  18. Have had significant blood loss, or have donated or received one or more units of blood within 6 weeks prior to enrolment
  19. Have a positive urine drug or positive breath alcohol screen at screening or enrolment
  20. Any disease or condition (medical or surgical) that might compromise haematological, cardiovascular, pulmonary, renal, gastrointestinal, or central nervous system function; or any other conditions that might interfere with the absorption, distribution, metabolism, or excretion of the investigational product, or that would place the participant at increased risk, as determined by the Investigator
  21. Regular use of, or have received, any concomitant prescription, over-the-counter, or herbal medications or nutritional supplements within 14 days prior to enrolment
  22. Any condition(s) that, in the opinion of the Investigator, might interfere with adherence to trial requirements or evaluation of the trial objectives

Responsible Party: International Partnership for Microbicides, Inc.
ClinicalTrials.gov Identifier: NCT02877979     History of Changes
Other Study ID Numbers: IPM 042
First Posted: August 25, 2016    Key Record Dates
Last Update Posted: August 24, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes